Customize your JAMA Network experience by selecting one or more topics from the list below.
Current standard treatment for idiopathic sensorineural hearing loss is a tapering dose of oral corticosteroids. However, results from uncontrolled case series have suggested that intratympanic corticosteroid injection may achieve similar rates of hearing improvement. In a randomized, noninferiority trial that involved 250 patients with sensorineural hearing loss, Rauch and colleagues Article compared the effect of oral prednisone vs intratympanic methylprednisolone on hearing recovery assessed 2 months after treatment. The authors defined noninferiority as a less than 10-dB difference in hearing outcome between treatments and found that intratympanic treatment was not inferior to oral prednisone treatment. In an editorial, Piccirillo Article discusses sudden sensorineural hearing loss, its treatment, and questions for future investigation.
This Week in JAMA . JAMA. 2011;305(20):2037. doi:10.1001/jama.2011.695
Create a personal account or sign in to: